The role of aberrant glycosylation in autoimmune disease development and progression
Paper Details
The role of aberrant glycosylation in autoimmune disease development and progression
Abstract
Protein glycosylation is a covalent attachment of complex oligosaccharides to proteins and lipids, is a ubiquitous and essential post-translational modification (PTM) that significantly expands the functional diversity of the proteome. While fundamental to processes such as protein folding, trafficking, and signal transduction, disruptions in normal glycosylation are increasingly recognized as central drivers of immune dysregulation and tissue damage. This review provides an overview of N- & O-linked glycosylation mechanisms and evaluates their profound influence on protein stability, activity, and the pathophysiology of common autoimmune disorders. This review focus on recent literature, focusing on the pathways of endoplasmic reticulum (ER) and Golgi apparatus, alongside advancements in mass spectrometry-based glycomics, to explore the relationship between altered glycan structures and clinical disease states. Specific glycans are identified as hallmarks of various conditions: Immunoglobulin G (IgG) agalactosylation in Rheumatoid Arthritis and IBD; increased sialylation and N-glycan bisection in Type 1 Diabetes; and elevated N-acetylglucosamine in Systemic Lupus Erythematosus; in Celiac Disease, we highlight the mechanistic role of galactose-deficient IgA1 and the mislocalization of the receptor in facilitating pathogenic antigen trafficking serving as sensitive biomarkers for disease activity and treatment adherence, glycan alterations actively modulate the inflammatory milieu. These glycosylation pathways offer a promising frontier for therapeutic intervention. Continued integration of glycomics into personalized medicine is essential for improving the diagnostic and prognostic accuracy for patients suffering from multisystemic autoimmune diseases.
Águila S, Noto R, Luengo-Gil G, Espín S, Bohdan N, de la Morena-Barrio ME, Corral J. 2021. N-glycosylation as a tool to study antithrombin secretion, conformation, and function. International Journal of Molecular Sciences 22(2), 516.
Bakhtiar R, Guan Z. 2005. Electron capture dissociation mass spectrometry in characterization of post-translational modifications. Biochemical and Biophysical Research Communications 334(1), 1–8.
Bartlett DB, Connelly MA, AbouAssi H, Bateman LA, Tune KN, Huebner JL, Kraus WE. 2016. A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls. Arthritis Research and Therapy 18(1), 86.
Brazil JC, Parkos CA. 2022. Finding the sweet spot: glycosylation mediated regulation of intestinal inflammation. Mucosal Immunology 15(2), 211–222.
Breitling J, Aebi M. 2013. N-linked protein glycosylation in the endoplasmic reticulum. Cold Spring Harbor Perspectives in Biology 5(8), a013359.
Capuano M, Iaffaldano L, Tinto N, Montanaro D, Capobianco V, Izzo V, Sacchetti L. 2011. MicroRNA-449a overexpression, reduced NOTCH1 signals and scarce goblet cells characterize the small intestine of celiac patients. PLoS One 6(12), e29094.
Carrión-Barberà I, Triginer L, Tío L, Pérez-García C, Ribes A, Abad V, Lecube A. 2024. Role of advanced glycation end products as new biomarkers in systemic lupus erythematosus. International Journal of Molecular Sciences 25(5), 3022.
Chauhan K, Jandu JS, Brent LH, Al-Dhahir MA. 2023. Rheumatoid arthritis. StatPearls Publishing.
Cheng J, Kalliomäki M, Heilig HG, Palva A, Lähteenoja H, de Vos WM, Satokari R. 2013. Duodenal microbiota composition and mucosal homeostasis in pediatric celiac disease. BMC Gastroenterology 13(1), 113.
Clough J, Colwill M, Poullis A, Pollok R, Patel K, Honap S. 2024. Biomarkers in inflammatory bowel disease: a practical guide. Therapeutic Advances in Gastroenterology 17, 17562848241251600. DOI:10.1177/17562848241251600
Cremata J, Sorell L, Montesino R, Garcia R, Mata M, Cabrera G, Garrote J. 2003. Hypogalactosylation of serum IgG in patients with coeliac disease. Clinical and Experimental Immunology 133(3), 422–429.
Dai X, Fan Y, Zhao X. 2025. Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduction and Targeted Therapy 10(1), 102.
Demus D. 2024. Biomarker discovery in diabetes mellitus and lipid metabolism: multi-platform glyco(proteo)mic approaches. Leiden University.
Deng X, Liu X, Zhang Y, Ke D, Yan R, Wang Q, Hu C. 2023. Changes of serum IgG glycosylation patterns in rheumatoid arthritis. Clinical Proteomics 20(1), 7.
Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D. 1997. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nature Medicine 3(7), 797–801.
Eichler J. 2019. Protein glycosylation. Current Biology 29(7), R229–R231.
Hirata T, Kizuka Y, Lauc G, Trbojević-Akmačić I. 2021. The role of glycosylation in health and disease. Advances in Experimental Medicine and Biology 1325. Springer, Cham.
Kissel T, Toes RE, Huizinga TW, Wuhrer M. 2023. Glycobiology of rheumatic diseases. Nature Reviews Rheumatology 19(1), 28–43.
Kudelka MR, Stowell SR, Cummings RD, Neish AS. 2020. Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD. Nature Reviews Gastroenterology and Hepatology 17(10), 597–617.
Lebreton C, Ménard S, Abed J, Moura IC, Coppo R, Dugave C, Griffin M. 2012. Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology 143(3), 698–707.
Lindfors K, Suzuki H, Novak J, Collin P, Saavalainen P, Koskinen LL, Kaukinen K. 2011. Galactosylation of serum IgA1 O-glycans in celiac disease. Journal of Clinical Immunology 31(1), 74–79.
Lu R, Li P, Zhu L, Chang MX, Ouyang S. 2023. Advances in bacterial oligosaccharyltransferase structure elucidation and potential application to glycoconjugate vaccine design. Frontiers in Bioscience-Landmark 28(11), 305.
Lu X, Wang L, Wang M, Li Y, Zhao Q, Shi Y, Ji L. 2023. Association between immunoglobulin G N-glycosylation and lupus nephritis in female patients with systemic lupus erythematosus: a case-control study. Frontiers in Immunology 14, 1257906.
Lucier J, Mathias PM, Doerr C. 2024. Type 1 diabetes. In: StatPearls. StatPearls Publishing.
Marsh MN. 1992. Gluten, major histocompatibility complex, and the small intestine: a molecular and immunobiologic approach to the spectrum of gluten sensitivity. Gastroenterology 102(1), 330–354.
Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Lebreton C, Ménard S, Candalh C, Van Niel G. 2008. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. Journal of Experimental Medicine 205(1), 143–154.
Mayboroda OA, Lageveen-Kammeijer GS, Wuhrer M, Dolhain RJ. 2023. An integrated glycosylation signature of rheumatoid arthritis. Biomolecules 13(7), 1106.
McDowell C, Farooq U, Haseeb M. 2023. Inflammatory bowel disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470312/
Miyoshi E, Shinzaki S, Fujii H, Iijima H, Kamada Y, Takehara T. 2016. Role of aberrant IgG glycosylation in the pathogenesis of inflammatory bowel disease. PROTEOMICS–Clinical Applications 10(4), 384–390.
Molberg Ø, McAdam SN, Körner R, Quarsten H, Kristiansen C, Madsen L, Roepstorff P. 1998. Tissue transglutaminase selectively modifies gliadin peptides recognized by gut-derived T cells in celiac disease. Nature Medicine 4(6), 713–717.
Nemčić M, Tijardović M, Rudman N, Bulum T, Tomić M, Plavša B, Morahan G. 2023. N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at disease onset. Clinica Chimica Acta 543, 117298.
Oberhuber G, Granditsch G, Vogelsang H. 1999. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. European Journal of Gastroenterology and Hepatology 11(10), 1185.
Patrie SM, Roth MJ, Kohler JJ. 2012. Introduction to glycosylation and mass spectrometry. In: Mass spectrometry of glycoproteins: methods and protocols, pp. 1–17.
Patwary TA, Rahman M, Prottoy MNF, Alam SMD. 2025. Implications of aberrant glycosylation on age-related disease progression. International Journal of Bioscience 27(2), 176–188.
Pittschieler K, Ladinser B, Petell J. 1994. Reactivity of gliadin and lectins with celiac intestinal mucosa. Pediatric Research 36(5), 635–641.
Ramos-Martínez I, Ramos-Martínez E, Cerbón M, Pérez-Torres A, Pérez-Campos Mayoral L, Hernández-Huerta MT, García-Montalvo IA. 2023. The role of B cell and T cell glycosylation in systemic lupus erythematosus. International Journal of Molecular Sciences 24(1), 863.
Robbe Masselot C, Cordier C, Marsac B, Nachury M, Léonard R, Sendid B. 2023. Human fecal mucin glycosylation as a new biomarker in inflammatory bowel diseases. Inflammatory Bowel Diseases 29(1), 167–171.
Rudman N, Gornik O, Lauc G. 2019. Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes. FEBS Letters 593(13), 1598–1615.
Rudman N, Kifer D, Kaur S, Simunović V, Cvetko A, Pociot F, Gornik O. 2022. Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG. Diabetologia 65(8), 1315–1327.
Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, Makharia GK. 2018. Global prevalence of celiac disease: systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 16(6), 823–836.
Szabó D, Gyebrovszki B, Szarka E, Auer F, Rojkovich B, Nagy G, Ács A. 2025. Immunoglobulin G subclass-specific glycosylation changes in rheumatoid arthritis. International Journal of Molecular Sciences 26(19), 9626.
Taylor AK, Lebwohl B, Snyder CL, Green PHR. 2025. Celiac disease. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.
Theodoratou E, Campbell H, Ventham NT, Kolarich D, Pučić-Baković M, Zoldoš V, Kennedy NA. 2014. The role of glycosylation in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology 11(10), 588–600.
Toft-Hansen H, Nielsen C, Biagini M, Husby S, Lillevang ST. 2013. Lectin staining shows no evidence of involvement of glycocalyx/mucous layer carbohydrate structures in development of celiac disease. Nutrients 5(11), 4540–4552.
Tran DT, Ten Hagen KG. 2013. Mucin-type O-glycosylation during development. Journal of Biological Chemistry 288(10), 6921–6929.
Vaillant AAJ, Goyal A, Varacallo MA. 2023. Systemic lupus erythematosus. StatPearls.
Wu H, Kohler J. 2019. Photocrosslinking probes for capture of carbohydrate interactions. Current Opinion in Chemical Biology 53, 173–182.
Xia B, Crusius J, Meuwissen S, Peña A. 1998. Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies. World Journal of Gastroenterology 4(5), 446.
Ząbczyńska M, Link-Lenczowski P, Pocheć E. 2021. Glycosylation in autoimmune diseases. In: The role of glycosylation in health and disease, pp. 205–218. Springer.
Zhang L, Ten Hagen KG. 2023. Organizational aspects of cell biology – Part 1: O-linked glycosylation. In: Encyclopedia of Cell Biology. Elsevier.
Md. Nafis Fuad Prottoy, Sayad Md. Didarul Alam*, 2026. The role of aberrant glycosylation in autoimmune disease development and progression. Int. J. Biosci., 28(6), 1-12.
Copyright © 2026 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.